Roche Holding AG
- Country
- ๐จ๐ญSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 864
- Registration Number
- NCT04544436
- Locations
- ๐บ๐ธ
Maine Medical Center, Scarborough, Maine, United States
๐ต๐ฑNeurocentrum Bydgoszcz sp. z o.o, Bydgoszcz, Poland
๐ต๐ฑIndywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak., Lublin, Poland
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 985
- Registration Number
- NCT04544449
- Locations
- ๐ฆ๐ท
Focus CECIC, Buenos Aires, Argentina
๐บ๐ธAlabama Neurology Associates, Homewood, Alabama, United States
๐บ๐ธSutter East Bay Medical Foundation, Berkeley, California, United States
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 461
- Registration Number
- NCT04540211
- Locations
- ๐ญ๐ฐ
Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Hong Kong
๐น๐ญChulalongkorn Hospital; Medical Oncology, Bangkok, Thailand
๐จ๐ณAffiliated Hospital of Chengde Medical University, Chengde City, China
A Worldwide Cancer Registry Enrolling Participants Profiled With a Next-Generation Sequencing Test
- Conditions
- First Posted Date
- 2020-08-27
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15000
- Registration Number
- NCT04529122
- Locations
- ๐จ๐ด
Instituto Cancerologรญa Medellin, Medellin, Colombia
๐ฆ๐ทInstituto Alexander Fleming, Buenos Aires, Argentina
๐ฆ๐ทHospital Italiano, Buenos Aires, Argentina
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- Conditions
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 518
- Registration Number
- NCT04524871
- Locations
- ๐บ๐ธ
UC Irvine Medical Center, Orange, California, United States
๐บ๐ธCity of Hope, Duarte, California, United States
๐บ๐ธUCLA Center for East; West Medicine, Santa Monica, California, United States
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 829
- Registration Number
- NCT04513925
- Locations
- ๐บ๐ธ
Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia, United States
๐บ๐ธIllinois Cancer Care, Peoria, Illinois, United States
๐บ๐ธNew England Cancer Specialists, Brunswick, Maine, United States
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 287
- Registration Number
- NCT04512066
- Locations
- ๐บ๐ธ
CNRI - Los Angeles, LLC, Pico Rivera, California, United States
๐บ๐ธNeuro-Behavioral Clinical Research, Inc., Canton, Ohio, United States
๐บ๐ธUptown Research Institute, Chicago, Illinois, United States
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
- Conditions
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 174
- Registration Number
- NCT04503551
- Locations
- ๐บ๐ธ
Kaiser Permanente Riverside Medical Center, Riverside, California, United States
๐บ๐ธCharleston Neuroscience Inst, Ladson, South Carolina, United States
๐บ๐ธSouthwest Retina Consultants, Durango, Colorado, United States
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 152
- Registration Number
- NCT04487067
- Locations
- ๐ฎ๐น
Arcispedale Santa Maria Nuova; Oncologia, Reggio Emilia, Emilia-Romagna, Italy
๐ฎ๐นIstituto Nazionale Dei Tumori; Dipartimento Chirurgia Generale - Unita' Trapianti Fegato, Milano, Lombardia, Italy
๐ฎ๐นAzienda Ospedaliera Di Rilievo Nazionale E Di Alta Specializzazione Garibaldi, Palermo, Sicilia, Italy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT04475848
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom